Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gavin D. Kenny is active.

Publication


Featured researches published by Gavin D. Kenny.


Journal of Controlled Release | 2011

Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo.

Gavin D. Kenny; Nazila Kamaly; Tammy Kalber; Leigh Brody; Meliz Sahuri; Elham Shamsaei; Andrew D. Miller; Jimmy D. Bell

RNA interference (RNAi) is being widely explored as a means of tumour therapy due to the specific and potent silencing of targeted genes. However, in vivo delivery of RNAi effectors, such as small interfering RNA (siRNA) and detection of delivery is fraught with problems. Here, we describe novel theranostic PEGylated siRNA nanoparticles termed liposome-entrapped siRNA (LEsiRNA) nanoparticles. Our LEsiRNA nanoparticles are MR sensitive, contain labels for fluorescence microscopy/histology and promote functional siRNA delivery to tumours in mice leading to a significant reduction in both Survivin expression and tumour growth. LEsiRNA nanoparticles, administered by intravenous injection, were shown to accumulate in xenograft tumours by MR contrast image enhancements 24h post-administration. Fluorescence microscopy was used to corroborate the MR results and simultaneously demonstrate co-localisation of nanoparticles and siRNA within the tumours. The LEsiRNA nanoparticle-mediated delivery of the anti-cancer Survivin siRNA causes significant reduction in tumour growth when compared to controls. Our results suggest that LEsiRNA nanoparticles can be valuable as an in vivo delivery agent for siRNA therapy to tumours.


Biomaterials | 2013

Multifunctional receptor-targeted nanocomplexes for the delivery of therapeutic nucleic acids to the Brain

Gavin D. Kenny; Alison Bienemann; Aristides D. Tagalakis; John A. Pugh; Katharina Welser; Frederick Campbell; Alethea B. Tabor; Helen C. Hailes; Steven S. Gill; Mark F. Lythgoe; Cameron W. McLeod; Edward White; Stephen L. Hart

Convection enhanced delivery (CED) is a method of direct injection to the brain that can achieve widespread dispersal of therapeutics, including gene therapies, from a single dose. Non-viral, nanocomplexes are of interest as vectors for gene therapy in the brain, but it is essential that administration should achieve maximal dispersal to minimise the number of injections required. We hypothesised that anionic nanocomplexes administered by CED should disperse more widely in rat brains than cationics of similar size, which bind electrostatically to cell-surface anionic moieties such as proteoglycans, limiting their spread. Anionic, receptor-targeted nanocomplexes (RTN) containing a neurotensin-targeting peptide were prepared with plasmid DNA and compared with cationic RTNs for dispersal and transfection efficiency. Both RTNs were labelled with gadolinium for localisation in the brain by MRI and in brain sections by LA-ICP-MS, as well as with rhodamine fluorophore for detection by fluorescence microscopy. MRI distribution studies confirmed that the anionic RTNs dispersed more widely than cationic RTNs, particularly in the corpus callosum. Gene expression levels from anionic formulations were similar to those of cationic RTNs. Thus, anionic RTN formulations can achieve both widespread dispersal and effective gene expression in brains after administration of a single dose by CED.


Journal of Controlled Release | 2014

PEGylation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, anionic nanocomplexes

Aristides D. Tagalakis; Gavin D. Kenny; Alison Bienemann; David McCarthy; Mustafa M. Munye; Hannah Taylor; Marcella Wyatt; Mark F. Lythgoe; Edward White; Stephen L. Hart

Non-viral vector formulations comprise typically complexes of nucleic acids with cationic polymers or lipids. However, for in vivo applications cationic formulations suffer from problems of poor tissue penetration, non-specific binding to cells, interaction with serum proteins and cell adhesion molecules and can lead to inflammatory responses. Anionic formulations may provide a solution to these problems but they have not been developed to the same extent as cationic formulations due to difficulties of nucleic acid packaging and poor transfection efficiency. We have developed novel PEGylated, anionic nanocomplexes containing cationic targeting peptides that act as a bridge between PEGylated anionic liposomes and plasmid DNA. At optimized ratios, the components self-assemble into anionic nanocomplexes with a high packaging efficiency of plasmid DNA. Anionic PEGylated nanocomplexes were resistant to aggregation in serum and transfected cells with a far higher degree of receptor-targeted specificity than their homologous non-PEGylated anionic and cationic counterparts. Gadolinium-labeled, anionic nanoparticles, administered directly to the brain by convection-enhanced delivery displayed improved tissue penetration and dispersal as well as more widespread cellular transfection than cationic formulations. Anionic PEGylated nanocomplexes have widespread potential for in vivo gene therapy due to their targeted transfection efficiency and ability to penetrate tissues.


Journal of Controlled Release | 2012

Lipid peptide nanocomplexes for gene delivery and magnetic resonance imaging in the brain

Michele J. Writer; Panagiotis G. Kyrtatos; Alison Bienemann; John A. Pugh; Andrew S. Lowe; Claudio Villegas-Llerena; Gavin D. Kenny; Edward White; Steven S. Gill; Cameron W. McLeod; Mark F. Lythgoe; Stephen L. Hart

Gadolinium-labelled nanocomplexes offer prospects for the development of real-time, non-invasive imaging strategies to visualise the location of gene delivery by MRI. In this study, targeted nanoparticle formulations were prepared comprising a cationic liposome (L) containing a Gd-chelated lipid at 10, 15 and 20% by weight of total lipid, a receptor-targeted, DNA-binding peptide (P) and plasmid DNA (D), which electrostatically self-assembled into LPD nanocomplexes. The LPD formulation containing the liposome with 15% Gd-chelated lipid displayed optimal peptide-targeted, transfection efficiency. MRI conspicuity peaked at 4 h after incubation of the nanocomplexes with cells, suggesting enhancement by cellular uptake and trafficking. This was supported by time course confocal microscopy analysis of transfections with fluorescently-labelled LPD nanocomplexes. Gd-LPD nanocomplexes delivered to rat brains by convection-enhanced delivery were visible by MRI at 6 h, 24 h and 48 h after administration. Histological brain sections analysed by laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) confirmed that the MRI signal was associated with the distribution of Gd3 + moieties and differentiated MRI signals due to haemorrhage. The transfected brain cells near the injection site appeared to be mostly microglial. This study shows the potential of Gd-LPD nanocomplexes for simultaneous delivery of contrast agents and genes for real-time monitoring of gene therapy in the brain.


Biomaterials | 2012

Multifunctional receptor-targeted nanocomplexes for magnetic resonance imaging and transfection of tumours

Gavin D. Kenny; Claudio Villegas-Llerena; Aristides D. Tagalakis; Frederick Campbell; Katharina Welser; Mauro Botta; Alethea B. Tabor; Helen C. Hailes; Mark F. Lythgoe; Stephen L. Hart

The efficient targeted delivery of nucleic acids in vivo provides some of the greatest challenges to the development of genetic therapies. We aim to develop nanocomplex formulations that achieve targeted transfection of neuroblastoma tumours that can be monitored simultaneously by MRI. Here, we have compared nanocomplexes comprising self-assembling mixtures of liposomes, plasmid DNA and one of three different peptide ligands derived from ApoE, neurotensin and tetanus toxin for targeted transfection in vitro and in vivo. Neurotensin-targeted nanocomplexes produced the highest levels of transfection and showed a 4.7-fold increase in transfected luciferase expression over non-targeted nanocomplexes in Neuro-2A cells. Transfection of subcutaneous Neuro-2A tumours in vivo with neurotensin-targeted nanocomplexes produced a 9.3-fold increase in gene expression over non-targeted controls. Confocal microscopy analysis elucidated the time course of DNA delivery with fluorescently labelled nanocomplex formulations in cells. It was confirmed that addition of a gadolinium lipid conjugate contrast agent allowed real time in vivo monitoring of nanocomplex localisation in tumours by MRI, which was maintained for at least 24 h. The peptide-targeted nanocomplexes developed here allow for the specific enhancement of targeted gene therapy both in vitro and in vivo, whilst allowing real time monitoring of delivery with MRI.


The Journal of Nuclear Medicine | 2014

Cardiac Hypoxia Imaging: Second-Generation Analogues of 64Cu-ATSM

Maxwell Handley; Rodolfo A. Medina; Erika Mariotti; Gavin D. Kenny; Karen Shaw; Ran Yan; Thomas R. Eykyn; Philip J. Blower; Richard Southworth

Myocardial hypoxia is an attractive target for diagnostic and prognostic imaging, but current approaches are insufficiently sensitive for clinical use. The PET tracer copper(II)-diacetyl-bis(N4-methylthiosemicarbazone) (64Cu-ATSM) has promise, but its selectivity and sensitivity could be improved by structural modification. We have therefore evaluated a range of 64Cu-ATSM analogs for imaging hypoxic myocardium. Methods: Isolated rat hearts (n = 5/group) were perfused with normoxic buffer for 30 min and then hypoxic buffer for 45 min within a custom-built triple-γ-detector system to quantify radiotracer infusion, hypoxia-dependent cardiac uptake, and washout. A 1-MBq bolus of each candidate tracer (and 18F-fluoromisonidazole for comparative purposes) was injected into the arterial line during normoxia, and during early and late hypoxia, and their hypoxia selectivity and pharmacokinetics were evaluated. The in vivo pharmacokinetics of promising candidates in healthy rats were then assessed by PET imaging and biodistribution. Results: All tested analogs exhibited hypoxia sensitivity within 5 min. Complexes less lipophilic than 64Cu-ATSM provided significant gains in hypoxic-to-normoxic contrast (14:1 for 64Cu-2,3-butanedione bis(thiosemicarbazone) (ATS), 17:1 for 64Cu-2,3-pentanedione bis(thiosemicarbazone) (CTS), 8:1 for 64Cu-ATSM, P < 0.05). Hypoxic first-pass uptake was 78.2% ± 7.2% for 64Cu-ATS and 70.7% ± 14.5% for 64Cu-CTS, compared with 63.9% ± 11.7% for 64Cu-ATSM. Cardiac retention of 18F-fluoromisonidazole increased from 0.44% ± 0.17% during normoxia to 2.24% ± 0.08% during hypoxia. In vivo, normoxic cardiac retention of 64Cu-CTS was significantly lower than that of 64Cu-ATSM and 64Cu-ATS (0.13% ± 0.02% vs. 0.25% ± 0.04% and 0.24% ± 0.03% injected dose, P < 0.05), with retention of all 3 tracers falling to less than 0.7% injected dose within 6 min. 64Cu-CTS also exhibited lower uptake in liver and lung. Conclusion: 64Cu-ATS and 64Cu-CTS exhibit better cardiac hypoxia selectivity and imaging characteristics than the current lead hypoxia tracers, 64Cu-ATSM and 18F-fluoromisonidazole.


Magnetic Resonance in Medicine | 2011

Slice profile correction for transmit sensitivity mapping using actual flip angle imaging

Shaihan J. Malik; Gavin D. Kenny; Joseph V. Hajnal

To enable clinical use of parallel transmission technology, it is necessary to rapidly produce transmit sensitivity (σ) maps. Actual flip angle imaging is an efficient mapping technique, which is accurate when used with 3D encoding and nonselective RF pulses. Mapping single slices is quicker, but 2D encoding leads to systematic errors due to slice profile effects. By simulating steady‐state slice profiles, we computed the relationship between σ and the signals received from the actual flip angle imaging sequence for arbitrarily chosen slice selective RF pulses. Pulse specific lookup tables were then used for reconstruction. The resulting σ‐maps are sensitive to T1 in a manner that depends strongly on the specific pulse, for example a precision of ±3% can be achieved by using a 3‐lobe sinc pulse. The method is applicable to any RF pulse; simulations must be performed once and thereafter fast reconstruction of σ‐maps is possible. Magn Reson Med, 2011.


Chemical Communications | 2011

Targeting of anionic membrane species by lanthanide(III) complexes: towards improved MRI contrast agents for apoptosis

Andrew J. Surman; Gavin D. Kenny; D. Krishna Kumar; Jimmy D. Bell; Duncan Casey; Ramon Vilar

In most healthy mammalian cells an uneven distribution of the mixture of the phospholipid species that make up the bilayer cell membrane is maintained between inner and outer layers: anionic species (principally phosphatidylserine, PS) are arranged largely on the inner layer. 1 In some abnormal cells this is not the case and a considerable amount of anionic lipids are displayed on the outer membrane surface; this is known in cells undergoing the early/intermediate stages of apoptosis (programmed cell death), 2 tumour vasculature, 3 bacteria and viruses. 4 Detection and imaging of apoptotic cells in vivo is desirable, as a clinical and research tool: the extent and speed of onset of apoptosis in tumours following a treatment has shown to be a good prognostic indicator of treatment outcome. 5 In vitro, apoptotic cells are typically detected using biomolecules known to bind phosphatidylserine, conjugated with fluorescent moieties; the most extensively used in this context has been Annexin V. 6 For in vivo imaging, Annexin V and others have been modified with various functionalities for imaging, for


Journal of Fluorine Chemistry | 2016

A bisphosphonate for 19F-magnetic resonance imaging

Gavin D. Kenny; Karen Shaw; Saranja Sivachelvam; Andrew J. P. White; René M. Botnar; Rafael T. M. de Rosales

Graphical abstract A water-soluble 1,1-geminal fluorinated bisphosphonate showing a single and narrow 19F resonance was synthesised and characterised. Its properties as contrast agent for 19F-MRI were evaluated in vitro and in vivo.


Organic and Biomolecular Chemistry | 2010

A novel bimodal lipidic contrast agent for cellular labelling and tumour MRI

Nazila Kamaly; Tammy Kalber; Gavin D. Kenny; Jimmy D. Bell; Michael R. Jorgensen; Andrew D. Miller

Collaboration


Dive into the Gavin D. Kenny's collaboration.

Top Co-Authors

Avatar

Stephen L. Hart

University College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jimmy D. Bell

University of Westminster

View shared research outputs
Top Co-Authors

Avatar

Mark F. Lythgoe

University College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge